A

R/R CLL Treated With Fixed-Duration Pirtobrutinib Combined With Venetoclax ± Rituximab: Updated BRUIN Study Results Including MRD Data

By ASH Conference 366 Videos FEATURING Nirav Shah
380 views
December 18, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Related Content

AUTOPLAY
12:47
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Feat. S. O'Brien, C. Coombs
17:05
Cleveland Clinic Taussig Cancer Institute

Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…

Feat. A. Winter
50:34
Scripps MD Anderson Cancer Center

The Cure of Leukemias in the Next Decade: An Optimist’s View

Feat. H. Kantarjian
06:53
UC Irvine Health

Fixed-Duration Treatment in CLL: Current Considerations

Feat. E. Brem
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
08:17
Adam Kittai

Highlights From iwCLL 2023: What's New and Practice Informing i…

06:56
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Efficacy of Ibrutinib Arms Across ALPINE an…

Feat. M. Shadman
15:21
5th SOHO Italy Annual Conference

How I Treat CLL at the MD Anderson Cancer Center

Feat. A. Ferrajoli
06:59
Constantine Tam

R/R CLL: A Matching-Adjusted Indirect Comparison of Zanubrutinib vs.…

10:06
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Results of A041702, an Alliance Phase 3 S…

Feat. J. Woyach
08:45
Insights from 2023 ASH Annual Meeting

The Best of CLL: Highlights & Key Takeaways

Feat. V. Yazbeck
06:34
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "A Matching-Adjusted Indirect Comparison o…

Feat. A. Kittai
10:19
Alvaro Alencar

Pirtobrutinib in R/R CLL

18:01
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Pri…

Feat. J. Rhodes
06:21
City of Hope

Cardiac Safety of Zanubrutinib vs. Other BTKis in CLL

Feat. A. Danilov
06:28
Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "Venetoclax + Obinutuzumab for Previously U…

Feat. O. Al-Sawaf
11:39
5th SOHO Italy Annual Conference

SOHO Italy 2023: Current Approach to Sequencing CLL Therapy in the R…

Feat. G. Gaidano
20:58
Andrew Lipsky

CLL: Recent Updates on the Use of BTK Inhibitors

22:47
Indy Hematology Review

CLL: Evaluating and Therapeutic Approaches for the Management of the…

Feat. J. Woyach
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…